REFERENCES
1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.
2. Ramesh S, Arachchige ASPM. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci. 2023;10:200-31.
3. Hu Y, Chen W, Wei C, et al. Pathological mechanisms of amyotrophic lateral sclerosis. Neural Regen Res. 2024;19:1036-44.
4. Mätlik K, Baffuto M, Kus L, et al. Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum. Nat Genet. 2024;56:383-94.
5. Charabati M, Wheeler MA, Weiner HL, Quintana FJ. Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting. Cell. 2023;186:1309-27.
6. Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186:693-714.
7. Fox NC, Belder C, Ballard C, et al. Treatment for Alzheimer’s disease. The Lancet. 2025;406:1408-23.
8. Shen H, Chen J, Liu M, et al. Research progress of extracellular vesicles derived from mesenchymal stem cells in the treatment of neurodegenerative diseases. Front Immunol. 2025;16:1496304.
9. Van Hoecke L, Lucci C, Vandenbroucke RE. Mesenchymal stromal cell extracellular vesicles as immune modulators and drug carriers in neurodegenerative disorders. Trends Neurosci. 2025;48:919-34.
10. Riazifar M, Mohammadi MR, Pone EJ, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano. 2019;13:6670-88.
11. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.
12. Welsh JA, Goberdhan DCI, O’Driscoll L, et al.; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
13. Chattopadhyay S, Rajendran RL, Chatterjee G, et al. Mesenchymal stem cell-derived exosomes: a paradigm shift in clinical therapeutics. Exp Cell Res. 2025;450:114616.
14. Levine KS, Leonard HL, Blauwendraat C, et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron. 2023;111:1086-93.e2.
15. Costa Sa AC, Madsen H, Brown JR. Shared molecular signatures across neurodegenerative diseases and herpes virus infections highlights potential mechanisms for maladaptive innate immune responses. Sci Rep. 2019;9:8795.
16. García-Domínguez M. Glial cell dynamics in neuroinflammation: mechanisms, interactions, and therapeutic implications. Biomedicines. 2026;14:115.
17. Ding M, Shen Y, Wang P, et al. Exosomes isolated from human umbilical cord mesenchymal stem cells alleviate neuroinflammation and reduce amyloid-beta deposition by modulating microglial activation in Alzheimer’s disease. Neurochem Res. 2018;43:2165-77.
18. Cone AS, Yuan X, Sun L, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer’s disease-like phenotypes in a preclinical mouse model. Theranostics. 2021;11:8129-42.
19. Kaniowska D, Wenk K, Rademacher P, et al. Extracellular vesicles of mesenchymal stromal cells can be taken up by microglial cells and partially prevent the stimulation induced by β-amyloid. Stem Cell Rev Rep. 2022;18:1113-26.
20. Bonafede R, Turano E, Scambi I, et al. ASC-exosomes ameliorate the disease progression in SOD1(G93A) murine model underlining their potential therapeutic use in human ALS. Int J Mol Sci. 2020;21:3651.
21. Provenzano F, Nyberg S, Giunti D, et al. Micro-RNAs shuttled by extracellular vesicles secreted from mesenchymal stem cells dampen astrocyte pathological activation and support neuroprotection in in-vitro models of ALS. Cells. 2022;11:3923.
22. Lin L, Huang L, Huang S, et al. MSC-derived extracellular vesicles alleviate NLRP3/GSDMD-mediated neuroinflammation in mouse model of sporadic Alzheimer’s disease. Mol Neurobiol. 2024;61:5494-509.
23. Zhou Y, Lu M, Du RH, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener. 2016;11:28.
24. Daga KR, Larey AM, Morfin MG, et al. Microglia morphological response to mesenchymal stromal cell extracellular vesicles demonstrates EV therapeutic potential for modulating neuroinflammation. J Biol Eng. 2024;18:58.
25. Falcicchia C, Tozzi F, Arancio O, Watterson DM, Origlia N. Involvement of p38 MAPK in synaptic function and dysfunction. Int J Mol Sci. 2020;21:5624.
26. Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 2019;16:3.
27. Xue C, Ma X, Guan X, Feng H, Zheng M, Yang X. Small extracellular vesicles derived from umbilical cord mesenchymal stem cells repair blood-spinal cord barrier disruption after spinal cord injury through down-regulation of Endothelin-1 in rats. PeerJ. 2023;11:e16311.
28. Shi Z, Sun H, Tian X, et al. Extracellular vesicles containing miR-181a-5p as a novel therapy for experimental autoimmune encephalomyelitis-induced demyelination. Int Immunopharmacol. 2024;135:112326.
29. Giunti D, Marini C, Parodi B, et al. Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. Sci Rep. 2021;11:1740.
30. Nakano M, Kubota K, Kobayashi E, et al. Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer’s disease model by increasing the expression of microRNA-146a in hippocampus. Sci Rep. 2020;10:10772.
31. Cui GH, Wu J, Mou FF, et al. Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in APP/PS1 mice. FASEB J. 2018;32:654-68.
32. Xu F, Wu Y, Yang Q, et al. Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer’s disease treatment. Adv Mater. 2022;34:e2207107.
33. Peng H, Li Y, Ji W, et al. Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson’s disease. ACS Nano. 2022;16:869-84.
34. Farinazzo A, Angiari S, Turano E, et al. Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis. Sci Rep. 2018;8:7473.
35. Campagna CE, Larey AM, Daga KR, et al. Development of a high-throughput morphological assay for evaluating mesenchymal stromal cell-derived extracellular vesicle modulation of brain pericyte secretory phenotype. Stem Cell Rev Rep. 2025;21:2781-95.
36. Marzookian K, Aliakbari F, Hourfar H, Sabouni F, Otzen DE, Morshedi D. The neuroprotective effect of human umbilical cord MSCs-derived secretome against α-synuclein aggregates on the blood-brain barrier. Int J Biol Macromol. 2025;304:140387.
37. Zhang C, Shao W, Yuan H, et al. Engineered extracellular vesicle-based nanoformulations that coordinate neuroinflammation and immune homeostasis, enhancing Parkinson’s disease therapy. ACS Nano. 2024;18:23014-31.
38. Phelps J, Hart DA, Mitha AP, Duncan NA, Sen A. Physiological oxygen conditions enhance the angiogenic properties of extracellular vesicles from human mesenchymal stem cells. Stem Cell Res Ther. 2023;14:218.
39. Varderidou-Minasian S, Lorenowicz MJ. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics. 2020;10:5979-97.
40. Weinberg SE, Chandel NS. Mitochondria reactive oxygen species signaling-dependent immune responses in macrophages and T cells. Immunity. 2025;58:1904-21.
41. Flores-Ponce X, Velasco I. Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease. Metabolomics. 2024;20:116.
42. McGill Percy KC, Liu Z, Qi X. Mitochondrial dysfunction in Alzheimer’s disease: guiding the path to targeted therapies. Neurotherapeutics. 2025;22:e00525.
43. Pedrini S, Sau D, Guareschi S, et al. ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum Mol Genet. 2010;19:2974-86.
44. Cunha-Oliveira T, Montezinho L, Mendes C, et al. Oxidative stress in amyotrophic lateral sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. 2020;2020:5021694.
45. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127:59-69.
46. Joshi DC, Chavan MB, Gurow K, Gupta M, Dhaliwal JS, Ming LC. The role of mitochondrial dysfunction in Huntington’s disease: Implications for therapeutic targeting. Biomed Pharmacother. 2025;183:117827.
47. Zhang Z, Kang J, Guo X, Jiang T, Li X. Energy-metabolic imbalance of oligodendrocytes in multiple sclerosis: mechanisms, network coupling, and advances in metabolism-targeted therapies. Biomedicines. 2025;13:2880.
48. Zhao M, Liu S, Wang C, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA. ACS Nano. 2021;15:1519-38.
49. Luo Q, Xian P, Wang T, et al. Antioxidant activity of mesenchymal stem cell-derived extracellular vesicles restores hippocampal neurons following seizure damage. Theranostics. 2021;11:5986-6005.
50. Mohamed AS, Abdel-Fattah DS, Abdel-Aleem GA, El-Sheikh TF, Elbatch MM. Biochemical study of the effect of mesenchymal stem cells-derived exosome versus L-Dopa in experimentally induced Parkinson’s disease in rats. Mol Cell Biochem. 2023;478:2795-811.
51. Ma J, Shi X, Li M, et al. MicroRNA-181a-2-3p shuttled by mesenchymal stem cell-secreted extracellular vesicles inhibits oxidative stress in Parkinson’s disease by inhibiting EGR1 and NOX4. Cell Death Discov. 2022;8:33.
52. He S, Wang Q, Chen L, He YJ, Wang X, Qu S. miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling. J Transl Med. 2023;21:747.
53. Zhang ZX, Zhou YJ, Gu P, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate Parkinson’s disease and neuronal damage through inhibition of microglia. Neural Regen Res. 2023;18:2291-300.
54. Zhang J, Zhao M, Yan R, et al. MicroRNA-7 protects against neurodegeneration induced by α-synuclein preformed fibrils in the mouse brain. Neurotherapeutics. 2021;18:2529-40.
55. Wang CC, Hu XM, Long YF, et al. Treatment of Parkinson’s disease model with human umbilical cord mesenchymal stem cell-derived exosomes loaded with BDNF. Life Sci. 2024;356:123014.
56. Wang H, Liu Y, Li J, et al. Tail-vein injection of MSC-derived small extracellular vesicles facilitates the restoration of hippocampal neuronal morphology and function in APP / PS1 mice. Cell Death Discov. 2021;7:230.
57. Chen HX, Liang FC, Gu P, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson’s disease model by inducing autophagy. Cell Death Dis. 2020;11:288.
58. Zhang Y, Bai X, Shen K, et al. Exosomes derived from adipose mesenchymal stem cells promote diabetic chronic wound healing through SIRT3/SOD2. Cells. 2022;11:2568.
59. Shi H, Deng HX, Gius D, Schumacker PT, Surmeier DJ, Ma YC. Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress. Hum Mol Genet. 2017;26:1915-26.
60. Bodart-Santos V, de Carvalho LRP, de Godoy MA, et al. Extracellular vesicles derived from human Wharton’s jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers. Stem Cell Res Ther. 2019;10:332.
61. Zhang X, Liu T, Hou X, et al. Exosomes secreted by mesenchymal stem cells delay brain aging by upregulating SIRT1 expression. Sci Rep. 2023;13:13213.
62. Zhang L, Ge Y, Wu J, Wang M, Huang N, Luo Y. Research on the application of mesenchymal stem cells for addressing mitochondrial damage in neurodegenerative diseases. Cell Mol Neurobiol. 2025;45:101.
63. Azman KF, Zakaria R. Recent advances on the role of brain-derived neurotrophic factor (BDNF) in neurodegenerative diseases. Int J Mol Sci. 2022;23:6827.
64. García-Domínguez M. Interplay between aging and glial cell dysfunction: implications for CNS health. Life. 2025;15:1498.
65. Xu W, Huang Y, Zhou R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell Mol Immunol. 2025;22:341-55.
66. Qin D, Wang C, Li D, Guo S. Exosomal miR-23a-3p derived from human umbilical cord mesenchymal stem cells promotes remyelination in central nervous system demyelinating diseases by targeting Tbr1/Wnt pathway. J Biol Chem. 2024;300:105487.
67. Katsuda T, Tsuchiya R, Kosaka N, et al. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci Rep. 2013;3:1197.
68. Xiong WP, Yao WQ, Wang B, Liu K. BMSCs-exosomes containing GDF-15 alleviated SH-SY5Y cell injury model of Alzheimer’s disease via AKT/GSK-3β/β-catenin. Brain Res Bull. 2021;177:92-102.
69. Wang X, Yang G. Bone marrow mesenchymal stem cells-derived exosomes reduce Aβ deposition and improve cognitive function recovery in mice with Alzheimer’s disease by activating sphingosine kinase/sphingosine-1-phosphate signaling pathway. Cell Biol Int. 2021;45:775-84.
70. Lee M, Ban JJ, Kim KY, et al. Adipose-derived stem cell exosomes alleviate pathology of amyotrophic lateral sclerosis in vitro. Biochem Biophys Res Commun. 2016;479:434-9.
71. Varderidou-Minasian S, Jakobs CE, Pasteuning-Vuhman S, et al. Mesenchymal stem cell-derived extracellular vesicle treatment of induced pluripotent stem cell-derived motor neurons with different amyotrophic lateral sclerosis genetic backgrounds. Neural Regen Res. 2026;21:5035-43.
72. Gschwendtberger T, Thau-Habermann N, von der Ohe J, Luo T, Hass R, Petri S. Protective effects of EVs/exosomes derived from permanently growing human MSC on primary murine ALS motor neurons. Neurosci Lett. 2023;816:137493.
73. Zamanian MY, Ivraghi MS, Gupta R, et al. miR-221 and Parkinson’s disease: a biomarker with therapeutic potential. Eur J Neurosci. 2024;59:283-97.
74. Zhai L, Shen H, Sheng Y, Guan Q. ADMSC Exo-MicroRNA-22 improve neurological function and neuroinflammation in mice with Alzheimer’s disease. J Cell Mol Med. 2021;25:7513-23.
75. Sha S, Shen X, Cao Y, Qu L. Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer’s disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/β-catenin pathway. Aging. 2021;13:15285-306.
76. Geng Y, Long X, Zhang Y, et al. FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson’s disease via m6A-dependent regulation of ATM mRNA. J Transl Med. 2023;21:652.
77. Chen YA, Lu CH, Ke CC, et al. Mesenchymal stem cell-derived exosomes ameliorate Alzheimer’s disease pathology and improve cognitive deficits. Biomedicines. 2021;9:594.
78. Guzhova IV, Lazarev VF, Kaznacheeva AV, et al. Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease. Hum Mol Genet. 2011;20:3953-63.
79. Davis AK, Pratt WB, Lieberman AP, Osawa Y. Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases. Cell Mol Life Sci. 2020;77:977-96.
80. Xin H, Li Y, Buller B, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012;30:1556-64.
81. Kim J, Inoue K, Ishii J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007;317:1220-4.
82. Lee HK, Finniss S, Cazacu S, Xiang C, Brodie C. Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression. Stem Cells Dev. 2014;23:2851-61.
83. Almeria C, Kreß S, Weber V, Egger D, Kasper C. Heterogeneity of mesenchymal stem cell-derived extracellular vesicles is highly impacted by the tissue/cell source and culture conditions. Cell Biosci. 2022;12:51.
84. Levy D, Jeyaram A, Born LJ, et al. Impact of storage conditions and duration on function of native and cargo-loaded mesenchymal stromal cell extracellular vesicles. Cytotherapy. 2023;25:502-9.
85. Ragni E, Perucca Orfei C, Papait A, de Girolamo L. Comparison of miRNA cargo in human adipose-tissue vs. amniotic-membrane derived mesenchymal stromal cells extracellular vesicles for osteoarthritis treatment. Extracell Vesicles Circ Nucl Acids. 2021;2:202-21.
86. Wang ZG, He ZY, Liang S, Yang Q, Cheng P, Chen AM. Comprehensive proteomic analysis of exosomes derived from human bone marrow, adipose tissue, and umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11:511.
87. Liu Y, Sun L, Li Y, Holmes C. Mesenchymal stromal/stem cell tissue source and in vitro expansion impact extracellular vesicle protein and miRNA compositions as well as angiogenic and immunomodulatory capacities. J Extracell Vesicles. 2024;13:e12472.
88. Xing X, Han S, Cheng G, Ni Y, Li Z, Li Z. Proteomic analysis of exosomes from adipose-derived mesenchymal stem cells: a novel therapeutic strategy for tissue injury. Biomed Res Int. 2020;2020:6094562.
89. Kehl D, Generali M, Mallone A, et al. Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. NPJ Regen Med. 2019;4:8.
90. Quan J, Liu Q, Li P, et al. Mesenchymal stem cell exosome therapy: current research status in the treatment of neurodegenerative diseases and the possibility of reversing normal brain aging. Stem Cell Res Ther. 2025;16:76.
91. Chen P, Wang F, Ling B, et al. Mesenchymal stem cell-derived extracellular vesicles: emerging therapies for neurodegenerative diseases. Int J Nanomedicine. 2025;20:8547-65.
92. Khan AA, T M de Rosales R. Radiolabelling of extracellular vesicles for PET and SPECT imaging. Nanotheranostics. 2021;5:256-74.
93. Su X, Wang H, Li Q, Chen Z. Extracellular vesicles: a review of their therapeutic potentials, sources, biodistribution, and administration routes. Int J Nanomedicine. 2025;20:3175-99.
94. Li S, Zhang J, Sun L, et al. Mesenchymal stem cell-derived extracellular vesicles: current advances in preparation and therapeutic applications for neurological disorders. Front Cell Dev Biol. 2025;13:1626996.
95. Zhang J, Buller BA, Zhang ZG, et al. Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system. Exp Neurol. 2022;347:113895.
96. Ye Y, Gao M, Shi W, et al. The immunomodulatory effects of mesenchymal stem cell-derived extracellular vesicles in Alzheimer’s disease. Front Immunol. 2023;14:1325530.
97. Wang XS, Wang Y, Xu Y, et al. Effectiveness of mesenchymal stem cell-derived extracellular vesicles therapy for Parkinson’s disease: a systematic review of preclinical studies. World J Stem Cells. 2025;17:102421.
98. Shen W, You T, Xu W, Xie Y, Wang Y, Cui M. Rapid and widespread distribution of intranasal small extracellular vesicles derived from mesenchymal stem cells throughout the brain potentially via the perivascular pathway. Pharmaceutics. 2023;15:2578.
99. Perets N, Betzer O, Shapira R, et al. Golden exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders. Nano Lett. 2019;19:3422-31.
100. Losurdo M, Pedrazzoli M, D’Agostino C, et al. Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer’s disease. Stem Cells Transl Med. 2020;9:1068-84.
101. Rossi B, Virla F, Angelini G, et al. Intranasal administration of extracellular vesicles derived from adipose mesenchymal stem cells has therapeutic effect in experimental autoimmune encephalomyelitis. Cells. 2025;14:1172.
102. Driedonks T, Jiang L, Carlson B, et al. Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina. J Extracell Biol. 2022;1:e59.
103. Haney MJ, Yuan H, Shipley ST, et al. Biodistribution of biomimetic drug carriers, mononuclear cells, and extracellular vesicles, in nonhuman primates. Adv Biol. 2022;6:e2101293.
104. Wan Z, Liu T, Xu N, et al. PKH dyes should be avoided in the EVs biodistribution study of the brain: a call for caution. Int J Nanomedicine. 2024;19:10885-98.
105. Zhao J, Yang J, Jiao J, Wang X, Zhao Y, Zhang L. Biomedical applications of artificial exosomes for intranasal drug delivery. Front Bioeng Biotechnol. 2023;11:1271489.
106. Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10:116.
107. Liu RY, Yin KF, He SY, et al. Viral infections and the risk of neurodegenerative diseases: a comprehensive meta-analysis and systematic review. Transl Psychiatry. 2025;15:388.
108. Barnes K. Infection with Epstein Barr virus increases risk of multiple sclerosis. Commun Med. 2022;2:13.
109. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296-301.
110. Wang AS, Perez JA, Gunzler SA. Frequency of Parkinson disease following COVID-19 infection: a two-year retrospective cohort study. Parkinsonism Relat Disord. 2023;111:105433.
112. Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9:815-27.
113. Shan D, Xu Y, Yang C, Crawford TJ, Holland C. COVID-19 infection associated with increased risk of new-onset vascular dementia in adults ≥50 years. npj Dement 2025;1:34.
114. Zhang T, Li Y, Pan L, et al. Brain-wide alterations revealed by spatial transcriptomics and proteomics in COVID-19 infection. Nat Aging. 2024;4:1598-618.
115. Nunes M, Kell L, Slaghekke A, et al. Virus-induced endothelial senescence as a cause and driving factor for ME/CFS and long COVID: mediated by a dysfunctional immune system. Cell Death Dis. 2026;17:16.
116. Seo D, Choi Y, Jeong E, et al. Distinct brain alterations and neurodegenerative processes in cognitive impairment associated with post-acute sequelae of COVID-19. Nat Commun. 2025;16:10552.
117. Greene C, Connolly R, Brennan D, et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024;27:421-32.
118. Yang X, Fontana A, Clouston SAP, Luft BJ. Increased phosphorylated tau (pTau-181) is associated with neurological post-acute sequelae of coronavirus disease in essential workers: a prospective cohort study before and after COVID-19 onset. EBioMedicine. 2026;123:106106.
119. de Andrade JR, de Farias JB, Vitorino ML de L, et al. Cerebrospinal fluid proteomic profiling reveals proteins associated with neuroinflammatory response in COVID-19 patients. ACS Omega. 2025;10:25489-97.
120. Bawne G, Coenen L, Nutma E, Middeldorp J, Lorenowicz MJ. When viruses talk through extracellular vesicles: a new perspective on Sars-Cov-2-Induced neurodegeneration. J Extracell Vesicles. 2026;15:e70272.
121. Orr N, Steinman L. Epstein-Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging. Proc Natl Acad Sci U S A. 2025;122:e2425670122.
122. Li DY, Choi ES, Bao X. HSV-1 as a potential driver of Alzheimer’s disease. Pathogens. 2025;14:1022.
123. Hosseinzadeh M, Pouladzadeh M, Khedri R, et al. Therapeutic potential of hUCMSC-derived exosomes in modulating inflammation and immune response in COVID-19-associated ARDS: a randomized clinical trial. Respir Med. 2025;249:108475.
124. Lightner AL, Sengupta V, Qian S, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized, Placebo-Controlled dosing clinical trial. Chest. 2023;164:1444-53.
125. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29:747-54.
126. Bligh R, Besancenez R. Safety and efficacy of bone marrow mesenchymal stem cell extracellular vesicles in long COVID patients: a case series. SRDT. 2024;10:1-7.
127. Laso-García F, Ramos-Cejudo J, Carrillo-Salinas FJ, et al. Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis. PLoS One. 2018;13:e0202590.
128. Hein ZM, Thazin, Kumar S, Che Ramli MD, Che Mohd Nassir CMN. Immunomodulatory mechanisms underlying neurological manifestations in long COVID: implications for immune-mediated neurodegeneration. Int J Mol Sci. 2025;26:6214.
129. Albornoz EA, Amarilla AA, Modhiran N, et al. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. 2023;28:2878-93.
130. Anderson FL, Biggs KE, Rankin BE, Havrda MC. NLRP3 inflammasome in neurodegenerative disease. Transl Res. 2023;252:21-33.
131. Paval NE, Căliman-Sturdza OA, Lobiuc A, Dimian M, Sirbu IO, Covasa M. MicroRNAs in long COVID: roles, diagnostic biomarker potential and detection. Hum Genomics. 2025;19:90.
132. Makki R, Kassem-Moussa S, Al Nemer F, et al. MicroRNAs in long COVID: key regulators, biomarkers, and therapeutic targets of post-SARS-CoV-2 sequelae. Biomolecules. 2026;16:283.
133. Appelman B, Charlton BT, Goulding RP, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024;15:17.
134. Charlton BT, Goulding RP, Jaspers RT, Appelman B, van Vugt M, Wüst RCI. Skeletal muscle adaptations and post-exertional malaise in long COVID. Trends in Endocrinology and Metabolism. 2025;36:614-22.
135. Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann Neurol. 2022;91:772-81.
136. Orsini F, Bosica M, Martucci A, et al. SARS-CoV-2 nucleocapsid protein induces tau pathological changes that can be counteracted by SUMO2. Int J Mol Sci. 2024;25:7169.
137. Montgomery S, Vingeliene S, Li H, et al. SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register-based cohort study. Brain Commun. 2024;6:fcae406.
138. Khodanovich M, Svetlik M, Kamaeva D, et al. Demyelination in patients with POST-COVID depression. J Clin Med. 2024;13:4692.
139. Lee SE, Choi H, Shin N, et al. Zika virus infection accelerates Alzheimer’s disease phenotypes in brain organoids. Cell Death Discov. 2022;8:153.
140. Fongsaran C, Jirakanwisal K, Peng BH, et al. Arbovirus infection increases the risk for the development of neurodegenerative disease pathology in the murine model. Brain Behav Immun Health. 2024;38:100780.
141. Grieco G, Piccolo S, Ragni E, de Girolamo L. Secretome and extracellular vesicle signatures in bone marrow-derived mesenchymal stromal cells after expansion in standard and next-generation media. Extracell Vesicles Circ Nucl Acids. 2025;6:195-215.
142. Li Y, Chen YH, Liu BY, et al. Deciphering the heterogeneity landscape of mesenchymal stem/stromal cell-derived extracellular vesicles for precise selection in translational medicine. Adv Healthc Mater. 2023;12:e2202453.
143. Crose JJ, Crose A, Ransom JT, Lightner AL. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2024;14:111-7.
